Archives
Anlotinib Hydrochloride: A Transformative Multi-Target Ty...
Anlotinib Hydrochloride: Empowering Advanced Cancer Research with Precision Angiogenesis Inhibition
Principle Overview: Mechanism and Research Rationale
Anlotinib hydrochloride (CAS 1058157-76-8) is a novel, small-molecule, multi-target tyrosine kinase inhibitor (TKI) designed to address the complexities of tumor angiogenesis and tyrosine kinase signaling pathway dysregulation. Developed as a potent anti-angiogenic small molecule, it primarily targets VEGFR2, PDGFRβ, and FGFR1—key drivers of endothelial cell proliferation, migration, and neovascularization—while exerting secondary effects on the ERK signaling pathway. In comparative preclinical assays, Anlotinib demonstrates superior inhibitory efficacy over established TKIs such as sunitinib, sorafenib, and nintedanib, with reported IC50 values of 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1. These data-driven metrics underscore its role as a comprehensive VEGFR2 PDGFRβ FGFR1 inhibitor and an indispensable tool for dissecting tumor angiogenesis inhibition in cancer research.
Pharmacokinetic profiling further positions Anlotinib as a research asset: it exhibits high oral bioavailability (up to 77% in dogs), favorable tissue distribution—especially in lung, liver, kidney, heart, and tumor tissue—and robust blood-brain barrier permeability. Minimal organ or genetic toxicity has been observed in preclinical safety studies, with a high LD50 (1735.9 mg/kg) and manageable systemic effects. Collectively, these characteristics make Anlotinib (hydrochloride) a versatile and reliable reagent for in vitro and in vivo modeling of cancer pathobiology, particularly for studies focusing on endothelial cell migration inhibition and capillary tube formation assays.
Experimental Workflow: Step-by-Step Protocol Enhancements
1. Preparation and Storage
- Aliquot Anlotinib hydrochloride upon arrival and store at -20°C to maintain reagent stability.
- Reconstitute in DMSO to prepare a concentrated stock solution (e.g., 10 mM), avoiding repeated freeze-thaw cycles.
2. Anti-Angiogenic Assays
- Endothelial Cell Migration Assay: Use human vascular endothelial cells (e.g., EA.hy 926) seeded in Boyden chambers or scratch/wound healing formats. Pre-treat cells with Anlotinib at gradient concentrations (1–100 nM), then stimulate migration using VEGF, PDGF-BB, or FGF-2. Quantify migrated cells after 6–24 hours. Anlotinib typically yields a concentration-dependent reduction in migration, with significant inhibition observed at low nanomolar ranges.
- Capillary Tube Formation Assay: Seed endothelial cells onto Matrigel-coated plates and treat with Anlotinib (e.g., 10, 50, 100 nM). Monitor tube formation over 4–16 hours using phase-contrast microscopy. Quantify total tube length, branch points, and number of loops. Expect marked inhibition of tube formation, even at concentrations as low as 10 nM, in line with reported IC50 values.
- Signaling Pathway Analysis: Following treatment, harvest cells and analyze ERK phosphorylation status via Western blotting or ELISA. Anlotinib should significantly reduce VEGF/PDGF-BB/FGF-2-induced ERK activation, confirming pathway targeting.
3. Advanced Applications
- Comparative Drug Benchmarking: Include parallel arms with sunitinib, sorafenib, or nintedanib to directly compare inhibitory potency and selectivity. Literature and product data consistently show Anlotinib’s superior inhibition of key angiogenic targets and greater sensitivity in functional assays.
- In Vivo Tumor Models: For translational studies, administer Anlotinib via oral gavage and monitor its effects on tumor growth, vascular density (CD31 immunostaining), and metastatic progression. High tissue accumulation, especially in tumor and lung, enables robust assessment of anti-tumor and anti-angiogenic efficacy.
Advanced Use Cases and Comparative Advantages
Recent case reports, such as the OncoTargets and Therapy study, reinforce Anlotinib’s translational impact. In a patient with intra-abdominal desmoplastic small round cell tumor (IADSRCT), Anlotinib administration resulted in significant regression of metastatic lesions after conventional therapies failed, with manageable toxicity. This clinical evidence mirrors preclinical findings: Anlotinib not only suppresses angiogenesis at the molecular level but also translates to meaningful tumor control in vivo, highlighting its relevance for research teams seeking to model therapy-resistant or aggressive cancers.
Further, Anlotinib’s broad target profile extends its utility beyond classical angiogenesis assays. By inhibiting multiple receptor tyrosine kinases—VEGFRs, FGFRs, PDGFRs, c-Kit, and Met—it enables researchers to interrogate complex signaling networks and potential resistance mechanisms in cancer models. This multi-targeted approach is particularly valuable in the context of tumor heterogeneity and adaptive resistance, making Anlotinib a preferred choice for studies that demand both depth and flexibility in tyrosine kinase signaling pathway interrogation.
Evidence-Based Resource Integration
For practical guidance and scenario-driven troubleshooting, several complementary resources are highly recommended:
- Enhancing Tumor Angiogenesis Assays with Anlotinib (hydrochloride) – This article offers lab-driven strategies for maximizing assay reproducibility and quantitative rigor. It complements the current guide by detailing hands-on solutions for variability in cell viability and migration endpoints.
- Optimizing Angiogenesis Assays with Anlotinib (hydrochloride) – Focusing on comparative performance and troubleshooting, this resource extends the discussion by benchmarking Anlotinib against legacy TKIs, echoing its superior reproducibility and sensitivity for cancer research workflows.
- Redefining Tumor Angiogenesis Research: Mechanistic Mastery – This thought-leadership piece explores the mechanistic breadth of Anlotinib and its impact on translational research, providing visionary context for future anti-angiogenic therapeutic discovery. It serves as a natural extension to the practical protocols described here.
Troubleshooting and Optimization: Best Practices for Reliable Results
- Compound Solubility: Ensure complete dissolution in DMSO; vortex and briefly sonicate if needed. Use freshly prepared working dilutions to avoid precipitation or potency loss.
- Assay Sensitivity: When optimizing migration or tube formation assays, titrate Anlotinib concentrations in small increments (e.g., 5 nM steps) to precisely define the minimum effective dose for your cell system.
- Control Selection: Always include vehicle (DMSO), positive (growth factor-stimulated), and negative (no stimulant) controls. For benchmarking, use equimolar doses of comparator TKIs to contextualize Anlotinib’s performance.
- Batch Consistency: Source Anlotinib from a reputable supplier such as APExBIO to ensure lot-to-lot consistency and purity, which are critical for reproducible results.
- Pharmacodynamics in In Vivo Models: Monitor plasma/tissue concentrations using LC-MS/MS to confirm target engagement, especially in studies involving blood-brain barrier permeability or organ-specific efficacy.
- Data Interpretation: Use quantitative image analysis software (e.g., ImageJ) for unbiased assessment of tube formation and migration. Normalize data to vehicle controls and report mean ± SD from multiple replicates to enhance statistical power.
Future Outlook: Next-Generation Applications and Translational Promise
With the continual evolution of cancer research paradigms, Anlotinib hydrochloride is poised for expanded roles in precision oncology. Its capacity to inhibit multiple pro-angiogenic and proliferative pathways makes it an ideal candidate for combination studies with immunotherapies or cytotoxic agents. Future assay designs may leverage Anlotinib’s unique pharmacokinetics—such as its high tumor and CNS accumulation—to explore mechanisms of metastatic suppression and blood-brain barrier penetration.
Furthermore, as emerging data from clinical and preclinical studies (see the OncoTargets and Therapy report) validate Anlotinib’s efficacy in therapy-refractory tumors, the research community is increasingly turning to multi-target TKIs for modeling resistance and adaptive signaling. With robust, scenario-driven protocols and best-practice troubleshooting now widely available, research teams can confidently deploy Anlotinib as both a discovery and validation tool in the ongoing fight against cancer.
For assured reagent quality and technical support, APExBIO remains the trusted supplier of Anlotinib (hydrochloride), serving the needs of cancer biologists and translational scientists worldwide.